Caplin Point Laboratories LtdNSE: CAPLIPOINT
Open the Caplin Point Laboratories Ltd page
Follow Caplin Point Laboratories LtdFree account. Get a note when Caplin Point Laboratories Ltd files.
Q1 FY27 results analysis · August 12, 2026

Caplin Point Laboratories Q1 FY27 Results Analysis: Revenue Jumps 19.6%, US PBT Margin Doubles (CAPLIPOINT)

+18.8%PAT year on year, Rs. 179.09 Cr
Cofacto ResearchPublished August 12, 20262 min readPositive read
Quick summary

Caplin Point Laboratories Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 610.36 Cr (+19.60% YoY) and PAT growth of +18.80% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateAugust 12, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 610.36 Cr (+19.60% YoY)
PAT (Q1)Rs. 179.09 Cr (+18.80% YoY)
EBITDA margin38.40% (+70 bps YoY)
EPS (Q1)Rs. 23.27 (+15.80% YoY)
Market capRs. 18,832.17 Cr
CMPRs. 2,472.40

Quarter Snapshot

Revenue grew 19.6% YoY, beating the 14-16% guidance, driven by strong US segment growth and margin expansion. EBITDA margin improved to 38.4% with operating leverage, while the US PBT margin more than doubled. Gross margin compression and RoW margin decline are watch items.

Key Investment Insights

Key Positives

  • Revenue grew 19.6% YoY to Rs.610.36 Cr, above the guided 14-16% range.
  • EBITDA grew 23.0% YoY to Rs.247.03 Cr with margin expansion to 38.4%.
  • US segment revenue grew 25.9% YoY to Rs.134.29 Cr, within the 25-30% guidance range.
  • US segment PBT margin doubled from 9.2% to 24.8% YoY, demonstrating scaling benefits.
  • Free cash reserves increased to Rs.1,502 Cr from Rs.1,471 Cr, reflecting strong cash generation.

Risk Factors

  • Gross margin contracted from 61.7% to 59.8% YoY due to inventory build and cost pressures.
  • Rest of World segment PBT margin declined from 37.5% to 33.3% YoY, pressured by product mix and tender business.
  • Employee costs grew 25.4% YoY, outpacing revenue growth of 19.6%.

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.